Regulatory considerations for Campylobacter vaccine development

Journal of Infectious Diseases

Volumn 176, Issue 6 SUPPL., 1997, Pages

  Kopecko, Dennis J ^a,b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

CAMPYLOBACTER JEJUNI; CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; PATHOGENESIS; PRIORITY JOURNAL; VACCINATION;

EID: 0030679553     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513797     Document Type: Conference Paper

References (5)

1. Skirrow MB, Blaser MJ. Campylobacter jejuni. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg MB, Guerrant RL, eds. Infections of the gastrointestinal tract. New York: Raven Press, 1995:825-48.
2. Mishu B, Blaser MJ. The role of Campylobacter jejuni in the initiation of Guillain-Barré syndrome. Clin Infect Dis 1993;17:104-8.
3. Anthony BF, Sutton A. The role of the Food and Drug Administration in vaccine testing and licensure. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. 2nd ed. New York: Marcel Dekker, 1997:1185-94.
4. Kaper JB, Tacket CO, Levine MM. New and improved vaccines against cholera. Part I: attenuated Vibrio cholerae O1 and O139 strains as live oral cholera vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. 2nd ed. New York: Marcel Dekker, 1997:447-57.
5. Hale TL, Venkatesan MM. Vaccines against Shigella infections. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. 2nd ed. New York: Marcel Dekker, 1997:843-52.